Compare Abeona Therapeutics Inc (ABEO) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Sirius XM Holdings Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Sirius XM Holdings Inc trades at $30.18 (market cap $10.34B). The key difference: Sirius XM Holdings Inc is far larger — about 27.7× Abeona Therapeutics Inc's market cap, and Sirius XM Holdings Inc pays a 3.52% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SIRI | |
|---|---|---|
Market Cap | $373.32M | $10.34B |
Sector | Health | Media |
52-Week High | $7.23 | $30.75 |
52-Week Low | $4.17 | $19.92 |
Enterprise Value | $228.22M | $20.01B |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Sirius XM (SIRI) trades at $30.71, up 0.66% on the day, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a P/E of 13.03 and a net income margin of 9.86%, supported by recent earnings beats. Analysts maintain a consensus Buy rating with a $31.17 price target, and the company continues to generate strong operating cash flow of $1.90B in 2025. Recent news highlights a new advertising partnership with Alphabet and upcoming Q2 2026 earnings.
The outlook for SIRI is positive, driven by consistent earnings performance and strategic partnerships. Key opportunities include dividend yield and potential index inclusion benefits. Risks involve high debt levels and competitive pressures in the media sector. The stock's current price near the consensus target suggests limited upside unless earnings exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
